Literature DB >> 21607712

Elevated serum levels of macrophage migration inhibitory factor and their significant correlation with rheumatoid vasculitis disease activity.

Kuninobu Wakabayashi1, Kumiko Otsuka, Michihito Sato, Ryo Takahashi, Tsuyoshi Odai, Takeo Isozaki, Nobuyuki Yajima, Yusuke Miwa, Tsuyoshi Kasama.   

Abstract

Macrophage migration inhibitory factor (MIF) is recognized to be an important mediator in several inflammatory disorders, including rheumatoid arthritis (RA) and vasculitis. To evaluate the role of MIF in rheumatoid vasculitis (RV), we determined serum levels of MIF by enzyme-linked immunosorbent assay in RA patients with and without vasculitis and assessed their relationship to disease activity. Serum was obtained from 95 RA patients during active disease states [49 without vasculitis, 35 with extra-articular manifestations without histologically proven vasculitis, and 11 with histologically proven vasculitis] and from 22 healthy individuals. Vasculitis disease activity was assessed using the Birmingham Vasculitis Activity Score (BVAS). MIF levels were significantly higher in RA patients than in controls. Moreover, MIF levels were significantly higher in RA patients with vasculitis than in those without vasculitic complications. In all RA patients, a statistically significant positive correlation was observed between serum MIF levels and each of the following: serum levels of C-reactive protein, rheumatoid factor, and thrombomodulin; and the erythrocyte sedimentation rate. In the RV group, the elevation of MIF levels correlated with the BVAS. Our findings suggest that MIF may serve as an additional serologic inflammatory marker of disease activity in RV, and it may be implicated in the pathogenesis of RV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21607712     DOI: 10.1007/s10165-011-0466-z

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  6 in total

1.  MIF, a potential therapeutic target for rheumatoid arthritis?

Authors:  Zhaolin Chen; Taotao Ma; Cheng Huang; Lei Zhang; Tingting Hu; Jun Li
Journal:  Rheumatol Int       Date:  2014-01-25       Impact factor: 2.631

Review 2.  Connective Tissue Disorder-Associated Vasculitis.

Authors:  Aman Sharma; Aadhaar Dhooria; Ashish Aggarwal; Manish Rathi; Vinod Chandran
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

Review 3.  Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis.

Authors:  Kyoung-Woon Kim; Hae-Rim Kim
Journal:  Korean J Intern Med       Date:  2016-05-12       Impact factor: 2.884

4.  Dengue virus enhances thrombomodulin and ICAM-1 expression through the macrophage migration inhibitory factor induction of the MAPK and PI3K signaling pathways.

Authors:  Trai-Ming Yeh; Shu-Hsiang Liu; Kao-Chang Lin; Chieh Kuo; Shu-Yun Kuo; Tzuu-Yuan Huang; Yong-Ren Yen; Rong-Kun Wen; Lien-Cheng Chen; Tsai-Feng Fu
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

5.  Elevated serum levels of macrophage migration inhibitory factor are associated with progressive chronic cardiomyopathy in patients with Chagas disease.

Authors:  Romina A Cutrullis; Patricia B Petray; Edgardo Schapachnik; Rubén Sánchez; Miriam Postan; Mariela N González; Valentina Martín; Ricardo S Corral
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

6.  In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine.

Authors:  Alagarraju Muthukumar; Madhusudhanan Narasimhan; Quan-Zhen Li; Lenin Mahimainathan; Imran Hitto; Franklin Fuda; Kiran Batra; Xuan Jiang; Chengsong Zhu; John Schoggins; James B Cutrell; Carol L Croft; Amit Khera; Mark H Drazner; Justin L Grodin; Benjamin M Greenberg; Pradeep P A Mammen; Sean J Morrison; James A de Lemos
Journal:  Circulation       Date:  2021-06-16       Impact factor: 29.690

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.